September 2022 - Volume 81 - 9

VIEWPOINT

1. Developing guidelines for ultrarare rheumatic disorders: a bumpy ride

RHEUMATOID ARTHRITIS

2. Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 

3. Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

4. Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis 

SPONDYLOARTHRITIS

5. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group 

6. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis 

SYSTEMIC LUPUS ERYTHEMATOSUS

7. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades 

8. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus 

9. Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study 

SYSTEMIC SCLEROSIS

10. Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching 

VASCULITIS

11. Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids 

AUTOIMMUNITY

12. Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component 

OSTEOPOROSIS

13. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease 

CRYSTAL ARTHROPATHIES

14. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis 

IMAGES IN RHEUMATOLOGY

15. Clinical image: bone erosions in a young man 

LETTERS

16. Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 

17. Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis 

18. Sequential interleukin-17/interleukin-23 inhibition in treatment-refractory psoriatic arthritis 

19. Determination of the minimal clinically important difference (MCID) of the physician global assessment (PGA) in SLE

20. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection 

21. Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine 

ELECTRONIC PAGES

22. More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia 

23. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli 

24. Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al 

25. Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al

26. Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis 

27. Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al 

28. Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al 

29. Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef et al’ by Lo et al 

30. Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al 

31. Response to: ‘‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al’ by Cui et al 

32. Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al 

33. Response to: ‘Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al’ by Colunga-Pedraza et al 

34. Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing 

35. Response to: ‘Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew–gender discrepancies at annual EULAR congresses: towards the gap narrowing’ by Conigliaro et al 

36. Case of postpartum axial spondyloarthritis 

37. Response to: ‘Case of postpartum axial spondyloarthritis’ by Furuhashi et al 

38. Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ 

39. Response to: ‘Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon et al 

40. Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care 

41. Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al 

42. Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries? 

43. Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al 

44. 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace et al 

45. Glucosamine and mortality: a note of caution 

46. Response to: ‘Glucosamine and mortality: a note of caution’ by Conway 

47. Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al 

48. Response to: ‘Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al’ by Yueh et al 

49. Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al 

50. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al 

51. Terminology and definition of ‘antinuclear antibodies’: history and current debate 

52. Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

PDF

ISSUE INFORMATION